Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Hendifar

Showing results (31-40 of 83) with videos related to

Pageof 9
Sort By:
Advances in Radiation Oncology|July 31, 2019
Palliative Radiation Therapy for Bone Metastases in Neuroendocrine NeoplasmsMichelle Guan, Ingrid He, Michael Luu, et al.
JCO Precision Oncology|August 20, 2025
Evaluating the Effect of <i>KRAS</i> Variants on Survival Outcomes and Therapy Response in Pancreatic CancerMatthew I Ebia, Edik M Blais, Yujie Cui, et al.
Clinical and Molecular Hepatology|July 23, 2023
Recent advances in the management of hepatocellular carcinomaKamya Sankar, Jun Gong, Arsen Osipov, et al.
Human Pathology|December 13, 2025
Gastric neuroendocrine tumors associated with acid suppressant drugs are frequently associated with very prolonged drug use and may show unconventional morphologiesMahzad Azimpouran, Kevin M Waters, Andrew E Hendifar, et al.
Pharmacogenetics and Genomics|November 7, 2008
Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancerGeorg Lurje, Andrew E Hendifar, Anne M Schultheis, et al.
NPJ Digital Medicine|July 16, 2019
Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patientsGillian Gresham, Andrew E Hendifar, Brennan Spiegel, et al.
Investigational New Drugs|October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Journal of the American College of Surgeons|February 5, 2026
Surgical and Oncologic Outcomes After Pancreatectomy for Pancreatic Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 and von Hippel-Lindau Syndrome: A Large, Multi-Institutional, Cohort StudyLiti Zhang, Marco Ventin, Shahrzad Arya, et al.
Contemporary Clinical Trials|November 14, 2017
Wearable activity monitors in oncology trials: Current use of an emerging technologyGillian Gresham, Jennifer Schrack, Louise M Gresham, et al.
Plos One|June 26, 2019
Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims dataAileen Baecker, Sungjin Kim, Harvey A Risch, et al.
Pageof 9

Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
Advances in Radiation Oncology|July 31, 2019
Palliative Radiation Therapy for Bone Metastases in Neuroendocrine NeoplasmsMichelle Guan, Ingrid He, Michael Luu, et al.
JCO Precision Oncology|August 20, 2025
Evaluating the Effect of <i>KRAS</i> Variants on Survival Outcomes and Therapy Response in Pancreatic CancerMatthew I Ebia, Edik M Blais, Yujie Cui, et al.
Clinical and Molecular Hepatology|July 23, 2023
Recent advances in the management of hepatocellular carcinomaKamya Sankar, Jun Gong, Arsen Osipov, et al.
Human Pathology|December 13, 2025
Gastric neuroendocrine tumors associated with acid suppressant drugs are frequently associated with very prolonged drug use and may show unconventional morphologiesMahzad Azimpouran, Kevin M Waters, Andrew E Hendifar, et al.
Pharmacogenetics and Genomics|November 7, 2008
Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancerGeorg Lurje, Andrew E Hendifar, Anne M Schultheis, et al.
NPJ Digital Medicine|July 16, 2019
Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patientsGillian Gresham, Andrew E Hendifar, Brennan Spiegel, et al.
Investigational New Drugs|October 20, 2022
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161Lakshmi Rajdev, Ju-Whei Lee, Steven K Libutti, et al.
Journal of the American College of Surgeons|February 5, 2026
Surgical and Oncologic Outcomes After Pancreatectomy for Pancreatic Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 and von Hippel-Lindau Syndrome: A Large, Multi-Institutional, Cohort StudyLiti Zhang, Marco Ventin, Shahrzad Arya, et al.
Contemporary Clinical Trials|November 14, 2017
Wearable activity monitors in oncology trials: Current use of an emerging technologyGillian Gresham, Jennifer Schrack, Louise M Gresham, et al.
Plos One|June 26, 2019
Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims dataAileen Baecker, Sungjin Kim, Harvey A Risch, et al.
Pageof 9